【正文】 謝謝 第二十七頁(yè)，共二十七頁(yè)。中分子溶質(zhì) (相對(duì)分子質(zhì)量 500～ 30000)去除對(duì)患者預(yù)后的影響爭(zhēng)論由來(lái)已久［ 13］。 Page 26 第二十六頁(yè)，共二十七頁(yè)。 Page 25 [47] Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia[J]. Kidney Int,2024,62:15241538. [48] Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study[J]. Kidney Int ,1999,55:19451951. [49] Yilmaz MI, Carrero JJ, Ortiz A, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease[J]. Clin J Am Soc ephrol,2024,4:17161723. [50] Vallance P, Leone A, Calver A, Collier J, Moncada of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure[J]. Lancet,1992, 339:572575. [51] Passauer J, B252。 Page 23 [24] Troidle L, Hotchkiss M, Finkelstein F. A thrice weekly incenter nocturnal hemodialysis program[J]. Adv Chronic Kidney Dis ,2024,14:244248. [25] KalantarZadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing longterm hemodialysis[J]. Circulation,2024,119:671679. [26] Kliger AS. Highfrequency hemodialysis: rationale for randomized clinical trials[J]. Clin J Am Soc Nephrol,2024,2:390392. [27] Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis:a systematic review[J]. Clin J Am Soc Nephrol,2024,1:3342. [28] US Renal Data System. USRDS 2024 annual data report: atlas of chronic kidney disease and endstage renal disease in the United States[J]. 2024. ( :// ) [29] Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin among hemodialysis patients in Europe, Japan,and the United States: casemix effects[J]. Am J KidneyDis,2024,44:1621. [30] Foley RN, Hakim RM. Why is the mortality of dialysis patients in the United States much higher than the rest of the world[J]? J Am Soc Nephrol,2024,20:14321435. [31] 謝紅浪 ,季大璽 ,徐斌 ,等 . 1254例維持性血液透析患者長(zhǎng)期生存分析 [J].腎臟病不透析腎移植雜志 ,2024,14:136141. [32] Yoshino M, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality [J]. J Am Soc Nephrol ,2024,17:35103519. [33] Fellstr?m BC, Jardine AG, Schmeider RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis[J]. N Engl J Med, 2024,360:13951407.[Erratum,N Engl J ed,2024,362:1450.] [34] Wanner C, Krane V, M?z W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [J]. N Engl J Med ,2024,353:238248. [Erratum,N Engl J Med,2024,353:1640.] 第二十三頁(yè)，共二十七頁(yè)。 Page 21 參 考 文 獻(xiàn) [1] Scribner BH, Caner JE, Buri R, Quinton W. The technique ofcontinuous hemodialysis[J].Trans Am Soc Artif Intern Organs ,1960,6:88103. [2] Quinton W, Dillard D, Scribner BH. Cannulation of bloodvessels for prolonged hemodialysis[J]. Trans Am Soc Artif Intern Organs ,1960,6:104113. [3] Brescia MJ,Cimino JE,Appel K,et hemodialysisusing venipuncture and a surgically created arteriovenous fistula[J].N Engl J Med,1966